Vistim Labs is a technology company.
Vistim Labs has raised $810K across 1 funding round.
Vistim Labs has raised $810K in total across 1 funding round.
Vistim Labs has raised $810K in total across 1 funding round.
Vistim Labs's investors include 1984 Ventures, GoAhead Ventures, New Climate Ventures, Volition Capital, Eytan Elbaz, Jonathan Zweig, Nick Green, Yoav Amit.
Vistim Labs is a medtech company developing AI-powered brain imaging diagnostics to monitor neurological disorders like Alzheimer's, Parkinson's, dementia, and others.[1][2][4][5] Its flagship product, Ceregram, uses EEG-based evoked potential tomography to generate high-resolution brain maps, tracking biomarkers such as amyloid/tau accumulation, neurodegeneration, and cognitive deficits, enabling clinicians to assess treatment efficacy in real-time.[4][5][6] The company serves neurologists, clinicians, and pharma companies by replacing costly PET scans with accessible, in-clinic tools that support precision medicine, improve patient outcomes, and accelerate drug development.[1][3][4] Founded in 2021 and headquartered in Miami with operations in Salt Lake City, Vistim has raised funding from Alberta Innovates and others, achieving a key milestone in October 2025 when Ceregram launched for U.S. clinical use.[2][4]
Vistim Labs was founded in 2021 in Miami, Florida, by James Hamet, a serial neurotech entrepreneur with patents, publications, and prior experience as CEO of Neurable, a brain-computer-interface leader.[2][7] The idea emerged from research at Columbia Medical Center, addressing the need for precision monitoring in dementia care—projected to affect 9 million Americans by 2050 at a $1 trillion cost—where existing biomarkers like amyloid fail to reliably track therapy responses.[2][5][6] Early traction came through lab support from Altitude Lab, clinical collaborations validating against PET/CSF biomarkers, and partnerships across the U.S., Latin America, and Europe.[3][6] Pivotal moments include demonstrating predictive power over amyloid SUVR in trials and launching Ceregram in 2025, shifting from R&D to clinical deployment.[4][6]
Vistim rides the AI-medtech wave in neurodegeneration, where aging populations drive demand for scalable diagnostics amid breakthroughs in Alzheimer's/Parkinson's therapies like anti-amyloid drugs.[2][4][6] Timing aligns with FDA pushes for AI as medical devices (AIaMD) and post-2025 launches of disease-modifying treatments needing real-world monitoring tools.[4][5] Market forces favor it: EEG's low cost/accessibility disrupts $multi-billion PET imaging, while precision medicine mandates personalized tracking to avoid mistreatment.[2][6] Vistim influences the ecosystem by validating digital biomarkers against gold standards, partnering on trials for Parkinson's/TBI/schizophrenia, and enabling pharma to market therapies via objective endpoints—potentially standardizing in-clinic brain health evaluation.[3][6]
Vistim Labs stands at an inflection point post-Ceregram launch, poised to scale nationwide adoption in neurology offices while expanding validations for broader indications like schizophrenia and TBI.[4][6] Key trends—AI biomarker integration, tele-neurology growth, and global dementia crises—will propel it, with collaborations yielding publications and larger trials to cement clinical evidence.[6][7] Influence may evolve from niche monitor to ecosystem enabler, powering pharma pipelines and redefining care standards, ultimately delivering on its promise of visible therapy impacts for millions. This positions Vistim as a linchpin in accessible brain health innovation.[1][5]
Vistim Labs has raised $810K across 1 funding round. Most recently, it raised $810K Seed in February 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2023 | $810K Seed | 1984 Ventures, GoAhead Ventures, New Climate Ventures, Volition Capital, Eytan Elbaz, Jonathan Zweig, Nick Green, Yoav Amit |